Highest-materiality recent filing
Actinium submits NYSE American compliance plan after equity deficiency notice
Received NYSE American deficiency notice on May 27, 2026, for Section 1003(a)(ii): equity below required $4M.
Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.
Actinium board adopts annual Say-on-Pay vote following shareholder advisory vote
Shareholders at Nov 26, 2025 annual meeting preferred an annual Say-on-Pay frequency.
Actinium CFO Steve O'Loughlin resigns; CEO Sandesh Seth named principal financial officer
Steve O'Loughlin resigns as CFO effective Feb 27, 2026 to pursue other opportunities.
Actinium re-elects Shetty and Almenoff as Class III directors at 2025 annual meeting
Shetty elected with 5,032,369 for, 1,234,852 withheld; Almenoff with 5,284,503 for, 982,719 withheld.
Actinium dismisses Marcum, engages CBIZ CPAs as auditor after Marcum acquisition
Marcum LLP dismissed as independent auditor on May 8, 2025, due to CBIZ CPAs acquiring its attest business.
Sandesh Seth and Jeffrey W. Chell re-elected as Class II directors for three-year terms expiring at 2027 annual meeting.
Actinium appoints June Almenoff, M.D., Ph.D. to Board of Directors
Dr. Almenoff brings over 25 years of biopharma leadership; previously President and CMO of Furiex (acquired by Actavis/AbbVie for $1.2B).
FDA requires additional Phase 3 trial for Iomab-B; SIERRA alone not adequate for BLA filing
SIERRA met primary endpoint (dCR) with p<0.0001, but FDA now demands overall survival benefit in randomized head-to-head trial.
David Nicholson re-elected: 3,959,659 for, 3,275,844 withheld, 9,087,835 broker non-votes.
Actinium confirms no deposits or accounts at Silicon Valley Bank
Company holds no deposits, securities, or accounts at SVB.
Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML
Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).
Actinium shareholders approve 3.5M share increase for 2019 Plan; Shetty re-elected
Shareholders approved an amendment to the 2019 Stock Plan increasing authorized shares by 3.5M to a total of 9,333,333 shares.
Actinium adjourns 2022 annual meeting to Dec 30 for more stockholder voting
Meeting originally scheduled Dec 8, 2022 adjourned to allow more time for voting.
Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)
Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.
Actinium amends at-the-market sales agreement, adds B. Riley Securities as agent
Original Capital on Demand Sales Agreement (Aug 2020) allowed up to $200M in ATM offerings via JonesTrading.
Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones
Upfront payment of $35 million from Immedica upon signing.
Actinium shareholders re-elect two Class II directors; approve 2.75M share increase to 2019 Plan
Sandesh Seth and Jeffrey W. Chell re-elected as Class II directors for term expiring at 2024 annual meeting.
On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)
Max materiality 0.90 · Median 0.43 · Most common event other_material